RxDoctor Payments Data

Wissam Shaya, MD

Family Medicine · Jacksonville, FLNPI 1003010349

Payments from drug & device makers

$3,030in general payments, 2019–2025

Across 110 payments — averaging $27.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$476
  • AbbVie$287
  • Lilly USA, LLC$231
  • Amgen$227
  • Exact Sciences$195
  • Dexcom, Inc.$192
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$3,030100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,030 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$81,253
Medicare patients
122
Services billed
1,660

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide67$103,265
EliquisApixaban32$38,959
JardianceEmpagliflozin21$24,167
MounjaroTirzepatide18$22,262
Breo ElliptaFluticasone/Vilanterol11$10,042
SymbicortBudesonide/Formoterol Fumarate26$7,734
XareltoRivaroxaban11$6,489
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$5,165
Varenicline Tartrate13$4,930
Humalog Kwikpen U-100Insulin Lispro14$3,579
Rosuvastatin Calcium317$3,002
Omeprazole114$2,221
Metoprolol Succinate167$1,951
Gabapentin59$1,598
Atorvastatin Calcium177$1,464

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$476$103,26567 claims
PfizerEliquis$85$38,95932 claims
Boehringer IngelheimJardiance$16$24,16721 claims
Lilly USA, LLCMounjaro$231$22,26218 claims
GSKBreo Ellipta$43$10,04211 claims
AstraZenecaSymbicort$127$7,73426 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →